Anti-VEGF use for ROP is expanding beyond bevacizumab and ranibizumab, with aflibercept’s fusion-protein structure conferring systemic exposure characteristics distinct from antibody-based agents.
Harrow, Inc. is rapidly evolving into a dominant US ophthalmic pharma player, with a 30-fold revenue increase since 2015 and ...
A major study links Wegovy to a rare form of sudden vision loss, and finds men may face three times the risk of women.
Executives from 4D Molecular Therapeutics (NASDAQ:FDMT) outlined the company’s gene therapy platform, clinical progress, and commercialization plans during a Barclays analyst discussion in Miami, ...
Amgen stock holds above key SMAs as strong drug sales, biosimilars, and MariTide pipeline momentum offset looming patent losses and pricing headwinds.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results